title

Pfizer just posted better-than-expected Q1 results and stuck to its full-year guidance despite Covid product declines. But what really stands out are the newer drugs stepping up—will this be enough to navigate upcoming patent cliffs?

Treasury yields slipped slightly as traders brace for the Fed's big decision. With over 90% odds of a hold, the real story may come from the chair's tone and Thursday's inflation numbers. What happens next could shift portfolios fast.

The US launched a daring strike on Iran's nuclear sites, but what made Operation Midnight Hammer so precise? Dive into the details of this historic mission...